Cancer 
        Digest        

The complex interactions of hormone receptors often can result in treatment resistance for patients with HR+ and HER2+ advanced breast cancer. – Image credit Penn Medicine. CANCER DIGEST – June 27, 2026 – The U.S. Food and Drug Administration has approved the targeted drug palbociclib in combination with standard therapies for adult patients with hormone receptor-positive (HR+) and HER2-positive (HER2+) often called triple positive locally advanced or metastatic breast cancer

Women who used GLP-1 medications were about 30 percent less likely to develop breast cancer than similar women who did not use the drugs, according to a new retrospective study led by researchers at University of Pennsylvania

Scientists have discovered a new and previously undescribed virus that infects gut bacteria in patients with colorectal cancer.

Low doses of vitamin D can enhance the effectiveness of chemotherapy given to women being treated for breast cancer.

atients given a course of immunotherapy prior to surgery for colon cancer remain cancer-free nearly three years later.

Results of an early stage clinical trial testing a new treatment has shown surprisingly high response rates with few side effects among the first 40 patients treated for at least 18 months.